Search

Technetium Tc-99m tilmanocept

It achieves high overall accuracy in detecting SLN [A32169]. … Once reconstituted and labelled, technetium Tc99m tilmanocept is intended to be injected in close proximity to the tumor being diagnosed and employed in preoperative gamma detection imaging in combination

Ardeparin

Normiflo was withdrawn from the US market in March 2000. … Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500.

Sodium feredetate

Sodium lauryl sulfoacetate

Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.

Sulpiride

Sulpiride first appeared in published literature in 1967. … [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

Thrombomodulin Alfa

Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). … It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular

Hyaluronidase (human recombinant)

[L13338] The action of hyaluronidase was first described in 1936, and named in 1939. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]

Telisotuzumab vedotin

[L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

Fluvoxamine

It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. … Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.

Andusomeran

Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. … [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.